Document:

Exhibit

Exhibit 10(nn)

HUMANA INC.
RESTRICTED STOCK UNIT AGREEMENT WITH PERFORMANCE VESTING
AND AGREEMENT NOT TO COMPETE OR SOLICIT
UNDER THE 2011 STOCK INCENTIVE PLAN

THIS RESTRICTED STOCK UNIT AGREEMENT ("Agreement") made as of <award_date> (the “Date of Grant”) by and between HUMANA INC., a corporation duly organized and existing under the laws of the State of Delaware (hereinafter referred to as the "Company"), and <first_name> <middle_name> <last_name>, an employee of the Company (hereinafter referred to as "Grantee").
WITNESSETH:
WHEREAS, the Humana Inc. 2011 Stock Incentive Plan (the "Plan") was approved by the Company's Board of Directors (the "Board") and stockholders; and
WHEREAS, the Company desires to award to Grantee Restricted Stock Units in accordance with the Plan.
NOW, THEREFORE, in consideration of the award of Restricted Stock Units to Grantee, the promises and mutual covenants hereinafter set forth, and other good and valuable consideration, the Company and Grantee agree as follows:

I.    RESTRICTED STOCK UNIT GRANT

A.    Grant.  Subject to the terms and conditions hereinafter set forth, and in accordance with the provisions of the Plan, the Company hereby grants to Grantee, and Grantee hereby accepts from the Company <shares_awarded> Performance-Based Restricted Stock Units (the “Restricted Stock Units”) (which represents the target amount of shares available as set out on Appendix A.  Each Restricted Stock Unit represents the right of the Grantee to receive (i) one (1) Share on the date of distribution provided for in Section 1.E.  In addition, the Grantee shall also have the right to receive all of the cash or in-kind dividends that are paid with respect to the Shares represented by the Restricted Stock Units to which this award relates (“DERs”).   Dividend equivalents with respect to any such Share shall be paid on the same date that such Share is issued to the Grantee pursuant to Section I.E. hereof.  The DERs shall be subject to the same terms and conditions applicable to the Restricted Stock Units, including, without limitation, the restrictions and non-transferability, vesting, forfeiture and distribution provisions contained in Sections I.B through I.E., inclusive, of this Agreement.  In the event that the Restricted Stock Units are forfeited pursuant to Section I.D. hereof, the related DER shall also be forfeited.
B.    Restrictions and Non-Transferability.  The Restricted Stock Units and DERs may not be sold, transferred, pledged, assigned or otherwise alienated or hypothecated.  In addition, such Restricted Stock Units and DERs shall be subject to forfeiture in accordance with the provisions of Section I.D.  
C.    Vesting of Shares.  Subject to the terms set forth below, if as of the third anniversary of the Date of Grant (the “Vest Date”), the Grantee and the Company have achieved the performance goals to be set forth in Appendix A, the Restricted Stock Units and related DERs shall vest to the extent such performance goals have been achieved.  

Effective on the Vest Date, any portion of the Restricted Stock Units and the related DERs for which the performance goals set forth in Appendix A have not been satisfied shall be immediately forfeited. However, (i) all of the unvested Restricted Stock Units and DERs will immediately vest at target level on (A) the date of termination due to the death of the Grantee or (B) the date of termination of the Grantee’s employment by the Company or its applicable affiliate for any reason other than Cause, or by the Grantee with Good Reason (as defined below), in each case within two (2) years following a Change in Control (a “Change in Control Termination”), if such termination of employment occurs prior to a Vesting Date or (ii) upon the termination of the Grantee’s employment due to Retirement, a prorated portion of the Restricted Stock Units (and related DERs) that would have vested on the next scheduled Vesting Date shall vest on the next scheduled Vesting Date, with the proration to be determined by calculating the product of (A) the quotient of (x) the number of completed months the Grantee has been employed since the Date of Grant or the most recent Vesting Date, as applicable, divided by (y) the number of months in the current restricted Vesting Period, multiplied by (B) the total number of Restricted Stock Units that were scheduled to vest on the next scheduled Vesting Date. For purposes of the foregoing calculation, a month is complete on the day in the following month that corresponds to the Date of Grant.  For the purposes of this Agreement, “Good Reason” means, (a) if the Grantee is a party to an employment or a severance agreement with the Company or one of its Subsidiaries in which “Good Reason” is defined, the occurrence of any circumstances defined as “Good Reason” in such employment or severance agreement, or (b) if the Grantee is not a party to an employment or severance agreement with the Company or one of the Subsidiaries in which “Good Reason” is defined, the relocation of the Grantee’s office at which the Grantee is to perform his or her duties to a location more than thirty (30) miles from the location at which the Grantee performed his or her duties prior to the Change in Control.
D.    Forfeiture.    Upon the termination of Grantee's employment with the Company prior to the time the Restricted Stock Units have vested pursuant to Section I.C., other than a termination in the event of Grantee’s Retirement, death, Disability or a Change in Control Termination, the Restricted Stock Units and DERs shall thereupon be forfeited immediately by Grantee.  In the event of Grantee’s Retirement, a prorated portion of the Restricted Stock Units and DERs that would have vested on the next Vesting Date shall vest in accordance with Section I.C.(ii) and the Grantee shall forfeit the remaining unvested portion of the Restricted Stock Units and DERs; provided, however, that the Committee may determine, in its sole discretion, that some or all of the unvested Restricted Stock Units and DERs held by the Grantee that would otherwise be forfeited as of the date of Retirement shall vest.  For the avoidance of doubt, no Restricted Stock Units or DERs shall be forfeited upon Grantee’s termination of employment due to Disability, with such Restricted Stock Units and DERs continuing to vest in accordance with the Vesting Dates provided in Section I.C.
E.    Distributions.  The Company shall issue to Grantee (or, if applicable, the Grantee’s estate or personal representative) Shares (or such other securities or other property into which the Shares have been converted, with any partial Shares or other securities to be settled in cash) with respect to the Grantee’s Restricted Stock Units and dividend equivalents accrued pursuant to the DERs with respect to such Restricted Stock Units, within 30 days of the date that the Restricted Stock Units vest in accordance with Section I.C hereof; provided, however, that, to the extent that the Restricted Stock Units are considered deferred compensation subject to Section 409A of the Code and the Restricted 

Stock Units vest in connection with the Grantee’s Change in Control Termination, then unless the Change in Control is a Section 409A Change in Control, the distribution of  Shares (or such other securities or other property into which the Shares have been converted) shall not be accelerated to the vesting date but such distribution shall instead occur based on the Vesting Dates set forth in Section I.C. hereof.  A “Section 409A Change in Control” shall mean a Change in Control that also constitutes a “change in ownership or effective control” of the Company or a “change in ownership of a substantial portion of the assets of” the Company, in each case within the meaning of Section 409A of the Code.  Notwithstanding anything to the contrary contained herein, no Shares may be transferred to any person other than the Grantee unless such other person demonstrates to the reasonable satisfaction of the Company such person’s right to the transfer.   
F.    Taxes.  Federal, state and local income and employment taxes and other amounts as may be required by law to be collected by the Company (“Withholding Taxes”) in connection with the distribution of Shares, cash or other property or, to the extent applicable, vesting of the Restricted Stock Units or DERs hereunder, shall be paid by Grantee at such time.  Notwithstanding the foregoing, the Company shall withhold delivery of a number of Shares with a Fair Market Value as of the distribution date equal to the Withholding Taxes required to be withheld in connection with such distribution.  

II.    AGREEMENT NOT TO COMPETE AND AGREEMENT NOT TO SOLICIT.  Grantee acknowledges that Grantee’s continued employment with the Company and the grant of the Restricted Stock Units evidenced hereby is sufficient consideration for this Agreement, including, without limitation, the restrictions imposed by this Section II.

A.    Agreement Not To Compete. Grantee hereby covenants and agrees that for a period commencing on the date hereof and ending twelve (12) months after the effective date of Grantee's termination of employment with the Company, Grantee shall not, directly or indirectly, personally, or as an employee, officer, director, partner, member, owner, material shareholder, investor or principal of, or consultant or independent contractor with, another entity, engage in business with, be employed by, or render any consultation or business advice or other services with respect to, any business which provides or offers products or services which compete with any Company Business, in any geographic areas in which the Company and/or any of its affiliates is then currently doing Company Business.
B.    Agreement Not To Solicit. Grantee hereby covenants and agrees that for a period commencing on the date hereof and ending twelve (12) months after the effective date of Grantee's termination of employment with the Company, Grantee, directly or indirectly, personally, or as an employee, officer, director, partner, member, owner, material shareholder, investor or principal of, or consultant or independent contractor with, another entity, shall not:
1.    Interfere with the relationship of the Company and/or any of its affiliates and any of its employees, agents, representatives, consultants or advisors.
2.    Divert, or attempt to cause the diversion from the Company and/or any of its affiliates, any Company Business, nor interfere with relationships of the Company and/or any of its affiliates with its policyholders, agents, brokers, dealers, distributors, marketers, sources of supply or customers. 

3.    Solicit, recruit or otherwise induce or influence any employee of the Company and/or any of its affiliates to accept employment in any business which competes with the Company Business, in any of the geographic areas in which the Company and/or any of its affiliates is then currently doing Company Business.
C.    Definitions.
For purposes of Sections II.A and B, the following definitions apply. 
1.    “Company Business” shall mean any business related to a service or product offered by the Company and/or any of its affiliates during the two-year period immediately preceding the Grantee’s termination date that Grantee engaged in or rendered any consultation or business advice or other services with respect to, during Grantee’s employment with the Company and/or any of its affiliates. 
2    “Geographic area” shall mean any state, commonwealth or territory of the United States or any equivalent entity in any foreign country. 
D.    Effect of Termination of Employment other than a Change in Control Termination on Agreements Not to Compete and Not to Solicit.
1.    In the event Grantee voluntarily resigns or is discharged by Company with Cause at any time prior to the vesting of the Restricted Stock Unit, the prohibitions on Grantee set forth in Sections II.A and II.B shall remain in full force and effect.   
2.    In the event Grantee is discharged by Company other than with Cause prior to the vesting herein of the Restricted Stock Unit, the prohibitions set forth in Section II.A shall remain in full force and effect only if the Company, solely at its option, pays to Grantee an amount at least equal to Grantee's then current annual base salary, whether such amount is paid pursuant to this provision or pursuant to any other severance or separation plan or other plan or agreement between Grantee and Company. 
3.    In the event Grantee is discharged by Company other than with Cause prior to vesting herein of the Restricted Stock Unit, the prohibitions set forth in Section II.B above shall remain in full force and effect.
4.    After the vesting of the Restricted Stock Unit, the prohibitions on Grantee set forth herein shall remain in full force and effect, except as otherwise provided in Section II.E.
E.    Effect Of a Change In Control Termination on Agreements Not to Compete and Not to Solicit.
1.    Notwithstanding anything set forth in Section II.D., in the event of a Change in Control Termination, the prohibitions on Grantee set forth in Section II.A shall remain in full force and effect only if the acquirer or successor to the Company following the Change in Control shall, solely at its option, pay, within thirty (30) days following Grantee's employment termination date with the Company or its successor, to the Grantee the Non-Compete Payment.  Notwithstanding any previous agreement between Grantee and the Company relating to the prohibitions on Grantee set forth in Section II.A, the “Non-Compete Payment” shall be an amount at least equal to Grantee’s then current annual base salary, plus Grantee’s target potential bonus pursuant to any bonus plan in which Grantee participated as of the date of the Change in Control.  Such sums shall be in addition to any other amounts paid or payable to Grantee with respect to other change in control agreements.  For the avoidance of doubt, the provisions of this Section IIE shall supersede any agreement between Grantee and the Company relating to the prohibitions on Grantee set forth in Section II.A, with the exception of any similar agreement contained in (i) any employment agreement between Grantee and 

the Company, or (ii) any agreement between Grantee and the Company not related to the employment of Grantee by the Company.
2.    In the event of a Change in Control Termination, the prohibitions on Grantee set forth in Section II.B. shall remain in full force and effect.
F.    Governing Law. Notwithstanding any other provision herein to the contrary, the provisions of this Section II of the Agreement, shall be governed by, and construed in accordance with, the laws of the Commonwealth of Kentucky without regard to its conflicts or choice of laws rules or principles that might otherwise refer construction or interpretation of this Section II to the substantive law of another jurisdiction.
G.    Injunctive Relief; Invalidity of Any Provision.  Grantee acknowledges that (1) his or her services to the Company are of a special, unique and extraordinary character, (2) his or her position with the Company will place him or her in a position of confidence and trust with respect to the operations of the Company, (3) he or she will benefit from continued employment with the Company, (4) the nature and periods of restrictions imposed by the covenants contained in this Section II hereof are fair, reasonable and necessary to protect the Company, (5) the Company would sustain immediate and irreparable loss and damage if Grantee were to breach any of such covenants, and (6) the Company’s remedy at law for such a breach will be inadequate.  Accordingly, Grantee agrees and consents that the Company, in addition to the recovery of damages and all other remedies available to it, at law or in equity, shall be entitled to seek both preliminary and permanent injunctions to prevent and/or halt a breach or threatened breach by Grantee of any covenant contained in Section II hereof.  If any provision of this Section II is determined by a court of competent jurisdiction to be invalid in whole or in part, it shall be deemed to have been amended, whether as to time, area covered or otherwise, as and to the extent required for its validity under applicable law, and as so amended, shall be enforceable.  The parties further agree to execute all documents necessary to evidence such amendment.

III.    MISCELLANEOUS PROVISIONS

A.    Binding Effect & Adjustment.    This Agreement shall be binding and conclusive upon each successor and assign of the Company.  Grantee’s obligations hereunder shall not be assignable to any other person or entity. It is the intent of the parties to this Agreement that the benefits of any appreciation of the underlying Common Stock during the term of the Award shall be preserved in any event, including but not limited to a recapitalization, merger, consolidation, reorganization, stock dividend, stock split, reverse stock split, spin-off or similar transaction, or other change in corporate structure affecting the Shares, as more fully described in Sections 4.6 and 11 of the Plan.  All obligations imposed upon Grantee and all rights granted to Grantee and to the Company shall be binding upon Grantee's heirs and legal representatives.
B.    Amendment.  This Agreement may only be amended by a writing executed by each of the parties hereto.
C.    Governing Law.  Except as to matters of federal law and the provisions of Section II hereof, this Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware without regard 

to its conflict of laws rules. This Agreement shall also be governed by, and construed in accordance with, the terms of the Plan.
D.    No Employment Agreement.  Nothing herein confers on the Grantee any rights with respect to the continuance of employment or other service with the Company, nor will it interfere with any right the Company would otherwise have to terminate or modify the terms of Grantee's employment or other service at any time.
E.    Severability.  If any provision of this Agreement is or becomes or is deemed invalid, illegal or unenforceable in any relevant jurisdiction, or would disqualify this Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan, it shall be stricken and the remainder of the Agreement shall remain in full force and effect.
F.    Defined Terms.   Any term used herein and not otherwise defined herein shall have the same meaning as in the Plan.  Any conflict between this Agreement and the Plan will be resolved in favor of the Plan.  Any disputes or questions of right or obligation which shall result from or relate to any interpretation of this Agreement shall be determined by the Committee.  Any such determination shall be binding and conclusive upon Grantee and any person or persons claiming through Grantee as to any rights hereunder.
G.    Execution.  If Grantee shall fail to execute this Agreement, either manually with a paper document, or through the online grant agreement procedure with the Company’s designated broker-dealer, and, if manually executed, return the executed original to the Secretary of the Company, the Award shall be null and void.  The choice of form will be at the Company’s discretion.
H.    Section 409A.   All Restricted Stock Units granted pursuant to this Agreement are intended either to be exempt from Section 409A of the Code, or, if subject to Section 409A of the Code, to be administered, operated and construed in compliance with Section 409A of the Code and any guidance issued thereunder.  This Agreement and the Plan shall be administered in a manner consistent with this intent and any provision that would cause the Agreement or Plan to fail to satisfy the first sentence of this section shall have no force and effect. Notwithstanding anything contained herein to the contrary, Restricted Stock Units (and related DERs) that (a) constitute “nonqualified deferred compensation” as defined under Section 409A of the Code and (b) vest as a consequence of the Grantee’s termination of employment, shall not be delivered until the date that the Grantee incurs a “separation from service” within the meaning of Section 409A of the Code (or, if the Grantee is a “specified employee” within the meaning of Section 409A of the Code and any guidance issued thereunder, the date that is six months and one day following the date of such “separation from service” (or on the date of the Grantee’s death, if earlier)).  In addition, each amount to be paid or benefit to be provided to the Grantee pursuant to this Agreement that constitutes deferred compensation subject to Section 409A of the Code, shall be construed as a separate identified payment for purposes of Section 409A of the Code.  

IN WITNESS WHEREOF, Company has caused this Agreement to be executed on its behalf by its duly authorized officer, and Grantee has executed this Agreement, each as of the day first above written.            

	
							
	 
	 
	 
	 
	 
	"Company"
	 

	 
	 
	 
	 
	 
	 
	 

	ATTEST:
	 
	 
	 
	HUMANA INC.
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	BY:
	 
	 
	 
	BY:
	 
	 

	 
	Joseph C. Ventura
	 
	 
	 
	BRUCE D. BROUSSARD

	 
	Senior Vice President, Associate General Counsel & Corporate Secretary
	 
	 
	President & Chief Executive Officer

	 
	 
	 

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	“Grantee”

	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	<first_name> <middle_name> <last_name>EX-4.1

 Exhibit 4.1 

ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

November 3, 2017 

 TABLE OF CONTENTS 

 

									
	 	 	 	  	 	  	Page	 
	1.	 	 Registration Rights
	  	 	2	 
		 	1.1	  	Definitions	  	 	2	 
		 	1.2	  	Request for Registration.	  	 	4	 
		 	1.3	  	Company Registration	  	 	5	 
		 	1.4	  	Form S-3 Registration	  	 	5	 
		 	1.5	  	Obligations of the Company	  	 	6	 
		 	1.6	  	Information From Holders	  	 	8	 
		 	1.7	  	Expenses of Registration	  	 	8	 
		 	1.8	  	Underwriting Requirements	  	 	8	 
		 	1.9	  	Delay of Registration	  	 	9	 
		 	1.10	  	Indemnification	  	 	9	 
		 	1.11	  	Reports Under the Exchange Act	  	 	11	 
		 	1.12	  	Assignment of Registration Rights	  	 	11	 
		 	1.13	  	Limitations on Subsequent Registration Rights	  	 	12	 
		 	1.14	  	Lock-Up Agreement	  	 	12	 
		 	1.15	  	Termination of Registration Rights	  	 	13	 
	2.	 	 Covenants of the Company.
	  	 	14	 
		 	2.1	  	Delivery of Financial Statements	  	 	14	 
		 	2.2	  	Inspection	  	 	14	 
		 	2.3	  	Right of First Offer	  	 	15	 
		 	2.4	  	FCPA	  	 	16	 
		 	2.5	  	Key Person Insurance	  	 	16	 
		 	2.6	  	Termination of Covenants	  	 	16	 
	3.	 	Miscellaneous.	  	 	17	 
		 	3.1	  	Termination	  	 	17	 
		 	3.2	  	Entire Agreement	  	 	17	 
		 	3.3	  	Successors and Assigns	  	 	17	 
		 	3.4	  	Amendments and Waivers	  	 	17	 
		 	3.5	  	Notices	  	 	18	 
		 	3.6	  	Severability	  	 	18	 
		 	3.7	  	Additional Investors	  	 	18	 
		 	3.8	  	Governing Law	  	 	18	 
		 	3.9	  	Counterparts	  	 	18	 
		 	3.10	  	Titles and Subtitles	  	 	19	 
		 	3.11	  	Aggregation of Stock	  	 	19	 
		 	3.12	  	Effect on Prior Agreement	  	 	19	 

  
 -i- 

 ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

This Amended and Restated Investors’ Rights Agreement (the “Agreement”) is made as of November 3, 2017, by and
among Arcus Biosciences, Inc., a Delaware corporation (the “Company”), the investors listed on Exhibit A hereto, each of which is herein referred to as an “Investor” and collectively as the
“Investors” and the Key Holders (as defined below), each of whom is herein referred to as a “Key Holder.” 

RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series A Preferred
Stock, par value $0.0001 per share (the “Series A Preferred Stock”), and/or shares of Common Stock issued upon conversion thereof, and/or shares of the Company’s Series B Preferred Stock, par value $0.0001 per share (the
“Series B Preferred Stock”), and/or shares of Common Stock issued upon conversion thereof, and possess registration rights, information rights, rights of first offer and other rights pursuant to that certain Amended and Restated
Investors’ Rights Agreement dated as of August 15, 2016, by and among the Company, certain holders of Common Stock, par value $0.0001 per share (the “Common Stock”), and such Existing Investors (the
“Prior Agreement”); 
 WHEREAS, the Prior Agreement may be amended, and any provision therein waived, with the
consent of the Company and the holders of a majority of the outstanding Registrable Securities, not including the Key Holders’ Stock (as such terms are defined in the Prior Agreement); 

WHEREAS, the Existing Investors as holders of a majority of the outstanding Registrable Securities, not including the Key Holders’
Stock, desire to terminate the Prior Agreement and to accept the rights created pursuant hereto in lieu of the rights granted to them under the Prior Agreement; and 

WHEREAS, certain of the Investors are parties to that certain Series C Preferred Stock Purchase Agreement of even date herewith by
and among the Company and such Investors (the “Series C Agreement”), which provides that as a condition to the closing of the sale of the Company’s Series C Preferred Stock, par value $0.0001 per share
(the “Series C Preferred Stock” and collectively with the Series A Preferred Stock and the Series B Preferred Stock, the “Preferred Stock”), this Agreement must be executed and delivered by
such Investors, Existing Investors holding a majority of the outstanding Registrable Securities and the Company and the Key Holders. 

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, the Company and the Existing Investors hereby
agree that the Prior Agreement shall be superseded and replaced in its entirety by this Agreement, and the parties hereto further agree as follows: 

 AGREEMENT 

1.    Registration Rights. The Company and the Investors covenant and agree as follows: 

1.1    Definitions. For purposes of this Section 1: 

(a)    “Affiliate” means, with respect to a Holder, such Holder’s principal or any other Person who,
directly or indirectly, controls, is controlled by, or is under common control with the Holder or such Holder’s principal, including, without limitation, any Affiliated Fund of the Holder and any trustee of the Holder. For purposes of this
definition, the terms “controlling,” “controlled by,” or “under common control with” shall mean the possession, directly or indirectly, of (i) the power to direct or cause the direction of the
management and policies of a Holder, whether through the ownership of voting securities, by contract, or otherwise, or (ii) the power to elect or appoint at least 50% of the directors, managers, general partners, or persons exercising similar
authority with respect to such Holder; 
 (b)    “Affiliated Fund” means, with respect to a Holder that
is a limited liability company, a limited liability partnership or a limited partnership, a fund or entity managed by the same manager or managing member or general partner or management company or by an entity controlling, controlled by, or under
common control with such manager or managing member or general partner or management company. For purposes of this definition, the terms “controlling,” “controlled by,” or “under common control
with” shall mean the possession, directly or indirectly, of (i) the power to direct or cause the direction of the management and policies of a Holder, whether through the ownership of voting securities, by contract, or otherwise, or
(ii) the power to elect or appoint at least 50% of the directors, managers, general partners, or persons exercising similar authority with respect to such Holder; 

(c)    “Competitor” means a person or entity engaged, directly or indirectly (including through any
partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)) in the business of the Company, but shall not include (i) any financial investment firm or collective
investment vehicle solely by virtue of its ownership (and/or its Affiliates’ ownership) of an equity interest in any Competitor held solely for investment purposes or (ii) GV or any of its affiliated funds, solely as a result of any
affiliation between such fund and Alphabet Inc. (including any Affiliate of Alphabet Inc.); 
 (d)    “Exchange
Act” means the Securities Exchange Act of 1934, as amended (and any successor thereto) and the rules and regulations promulgated thereunder; 

(e)    “Excluded Registration” means a registration statement relating solely to the sale of securities
of participants in a Company stock plan, a registration relating to a corporate reorganization or transaction under Rule 145 of the Securities Act, or a registration in which the only common stock being registered is common stock issuable upon
conversion of debt securities which are also being registered; 
 (f)    “Form S-3” means such form under the Securities Act as in effect on the date hereof or any successor form under the Securities Act that permits significant incorporation by reference of the Company’s
subsequent public filings under the Exchange Act; 
 (g)    “Founders” means Terry Rosen and
Juan C. Jaen; 

  
 -2- 

 (h)    “GV” means, collectively, GV 2016, L.P. and GV 2017,
L.P.; 
 (i)    “Holder” means any Investor or Key Holder owning or having the right to acquire
Registrable Securities or any assignee thereof in accordance with Section 1.12 of this Agreement; 

(j)    “IPO” means a firm commitment underwritten public offering by the Company of shares of its Common
Stock; 
 (k)    “Key Holders” means (i) The Rosen 1996 Family Trust Dated June 28, 1996 and
(ii) Juan Carlos Jaen and Anita Galeana, as trustees of the Juan Carlos Jaen and Anita Galeana 2000 Trust; 

(l)    “Key Holders’ Stock” means the shares of Common Stock issued to the Key Holders; 

(m)    “Major Investor” means any Investor that, individually or together with such Investor’s
Affiliates, holds at least 1,300,000 shares of the Preferred Stock or the Common Stock issued upon conversion thereof (subject to adjustment for stock splits, stock dividends, combinations, reclassifications or the like); 

(n)    “Person” means any individual, corporation, partnership, trust, limited liability company,
association or other entity; 
 (o)    “Register,” “registered,” and
“registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration
statement or document; 
 (p)    “Registrable Securities” means (i) the shares of Common Stock
issuable or issued upon conversion of the Preferred Stock held by the Holders and any assignee thereof in accordance with Section 1.12 of this Agreement, (ii) the Key Holders’ Stock, provided, however, that for the
purposes of Section 1.2, 1.4 and 1.13, the Key Holders’ Stock shall not be deemed Registrable Securities and the Key Holders shall not be deemed Holders, and (iii) any other shares of Common Stock of the Company issued as (or issuable
upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares listed in (i) and (ii); excluding,
however, in all cases any Registrable Securities sold in a transaction in which the rights under this Agreement are not assigned, or any shares for which registration rights have terminated pursuant to Section 1.15 of this Agreement;

 (q)    The number of shares of “Registrable Securities then outstanding” shall be determined by the
number of shares of Common Stock outstanding which are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible securities which are, Registrable Securities; 

(r)    “Restated Certificate” means the Company’s Amended and Restated Certificate of Incorporation,
as the same may be amended from time to time hereafter; 

  
 -3- 

 (s)    “SEC” means the Securities and Exchange Commission;
and 
 (t)    “Securities Act” means the Securities Act of 1933, as amended (and any successor thereto)
and the rules and regulations promulgated thereunder. 
 1.2    Request for
Registration. 
 (a)    If the Company shall receive at any time after the earlier of (i) five years after
the date of this Agreement or (ii) six months after the effective date of the IPO, a written request from the Holders of a majority of the Registrable Securities then outstanding (the “Initiating Holders”) that
the Company file a registration statement under the Securities Act covering the registration of Registrable Securities with an anticipated aggregate offering price of at least $20,000,000, then the Company shall, within 20 days after receiving such
request, give written notice of such request to all Holders and shall, subject to the limitations of subsection 1.2(b), use all commercially reasonable efforts to cause to be registered under the Securities Act all of the Registrable Securities
that each such Holder has requested to be registered within 20 days after the mailing of such notice by the Company. 

(b)    If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an
underwriting, they shall so advise the Company as a part of their request and the Company shall include such information in the written notice referred to in subsection 1.2(a). The underwriter will be selected by the Company, which underwriter
shall be reasonably acceptable to a majority in interest of the Holders whose Registrable Securities are to be included in the underwriting. In such event, the right of any Holder to include Registrable Securities in such registration shall be
conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such
Holder) to the extent provided herein. The Company and all Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such
underwriting. Notwithstanding any other provision of this Section 1.2, if the underwriter advises the Company in good faith that marketing factors require a limitation of the number of shares to be underwritten, then the Company shall so advise
all Holders of Registrable Securities which would otherwise be underwritten pursuant hereto, and the number of shares of Registrable Securities that may be included in the underwriting shall be allocated among all participating Holders thereof,
including the Initiating Holders, in proportion (as nearly as practicable) to the amount of Registrable Securities of the Company owned by each participating Holder. In no event shall any Registrable Securities be excluded from such underwriting
unless all other securities are first excluded from such offering. Any Registrable Securities excluded from or withdrawn from such underwriting shall be withdrawn from registration. 

(c)    Notwithstanding the foregoing, if the Company shall furnish to the Initiating Holders a certificate signed by the
President of the Company stating that in the good faith judgment of the Board of Directors of the Company it would be seriously detrimental to the Company and its stockholders for such registration statement to be filed, the Company shall have the
right to defer such filing for a period of not more than 120 days after receipt of the request of the Initiating Holders; provided, however, that the Company may not utilize this right or the

  
 -4- 

 
similar right set forth in Section 1.4(b)(iii) more than once in any 12-month period, and provided, further, that the Company shall not
register any securities for the account of itself or any other stockholder during such 120-day period (other than in an IPO or an Excluded Registration). 

(d)    In addition, the Company shall not be obligated to effect, or to take any action to effect, any registration
pursuant to this Section 1.2: 
 (i)    After the Company has effected two (2) registrations pursuant to this
Section 1.2 and such registrations have been declared or ordered effective; 
 (ii)    During the period starting
with the date 90 days prior to the Company’s good faith estimate of the date of filing of, and ending on a date 180 days after the effective date of, a registration subject to Section 1.3 hereof; provided that the Company is actively
employing in good faith all commercially reasonable efforts to cause such registration statement to become effective; or 

(iii)    If the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately
registered on Form S-3 pursuant to a request made pursuant to Section 1.4 below. 

1.3    Company Registration. 

(a)    If (but without any obligation to do so) the Company proposes to register (including for this purpose a
registration effected by the Company for stockholders other than the Holders) any of its stock under the Securities Act in connection with the public offering of such securities solely for cash (other than an Excluded Registration), the Company
shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of each Holder given within 20 days after mailing of such notice by the Company in accordance with Section 3.5, the Company shall,
subject to the provisions of Section 1.8, use all commercially reasonable efforts to cause to be registered under the Securities Act all of the Registrable Securities that each such Holder has requested to be registered if any stock of the
Company is registered. 
 (b)    The Company shall have the right to terminate or withdraw any registration initiated by
it under this Section 1.3 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. The expenses of such registration shall be borne by the Company, in accordance with
Section 1.7 hereof. 
 1.4    Form S-3
Registration. In case the Company shall receive from any Holder or Holders of not less than 30% of the Registrable Securities then outstanding a written request or requests that the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will: 

(a)    promptly give written notice of the proposed registration, and any related qualification or compliance, to all
other Holders; and 

  
 -5- 

 (b)    use all commercially reasonable efforts to effect, as soon as
practicable, such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are
specified in such request, together with all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within 15 days after receipt of such written notice from
the Company; provided, however, that the Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this Section 1.4: (i) if Form S-3
is not available for such offering by the Holders; (ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other
securities (if any) at an aggregate price to the public of less than $10,000,000; (iii) if the Company shall furnish to the Holders a certificate signed by the President of the Company stating that in the good faith judgment of the Board of
Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such registration statement to be filed, in which case the Company shall have the right to defer such filing for a period of not more than 120 days
after receipt of the request of the Holder or Holders under this Section 1.4; provided, however, that the Company shall not utilize this right or the similar right set forth in Section 1.2(c) more than once in any 12-month period; (iv) if the Company has, within the 12-month period preceding the date of such request, already effected two registrations on Form S-3 for the Holders pursuant to this Section 1.4; (v) if the Company has already effected three registrations on Form S-3 for the Holders pursuant to
this Section 1.4; (vi) in any jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance unless the
Company is already qualified to do business or subject to service of process in that jurisdiction; or (vii) during the period ending 180 days after the effective date of a registration statement subject to Section 1.3. 

(c)    subject to the foregoing, the Company shall file a registration statement covering the Registrable Securities and
other securities so requested to be registered as soon as practicable after receipt of the request or requests of the Holders. Registrations effected pursuant to this Section 1.4 shall not be counted as demands for registration or registrations
effected pursuant to Sections 1.2 or 1.3, respectively. 
 1.5    Obligations of the
Company. Whenever required under this Section 1 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a)    Prepare and file with the SEC a registration statement with respect to such Registrable Securities and use all
commercially reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for up to
120 days, or until the distribution described in such registration statement is completed, if earlier. 
 (b)    Prepare
and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the
disposition of all securities covered by such registration statement for up to 120 days, or until the distribution described in such registration statement is completed, if earlier. 

  
 -6- 

 (c)    Promptly notify the Holders of the effectiveness of such registration
statement, and furnish to the Holders such numbers of copies of a prospectus, including any supplement to the prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to
facilitate the disposition of Registrable Securities owned by them. 
 (d)    Following the effective date of such
registration statement, notify the Holders of any request by the SEC that the Company amend or supplement such registration statement, or the associated prospectus. 

(e)    Use all commercially reasonable efforts to register and qualify the securities covered by such registration
statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do
business or to file a general consent to service of process in any such states or jurisdictions unless the Company is already qualified to do business or subject to service of process in that jurisdiction. 

(f)    In the event of any underwritten public offering, enter into and perform its obligations under an underwriting
agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder and other security holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 

(g)    Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus
relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or
omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing, such obligation to continue for 120 days or until the distribution described in
such registration statement is completed, if earlier. 
 (h)    Cause all such Registrable Securities registered
pursuant to this Section 1 to be listed on each national securities exchange or trading system on which similar securities issued by the Company are then listed. 

(i)    Provide a transfer agent and registrar for all Registrable Securities registered pursuant hereto and a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration. 
 (j)    Make
generally available to its security holders, and deliver to each Holder participating in the registration statement, an earnings statement of the Company that will satisfy the provisions of Section 11(a) of the Securities Act covering a period
of 12 months beginning after the effective date of such registration statement as soon as reasonably practicable after the termination of such 12-month period. 

  
 -7- 

 1.6    Information From
Holders. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the
Company such information regarding such Holder, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be required to effect the registration of such Holder’s Registrable Securities. The
Company shall have no obligation with respect to any registration requested pursuant to Section 1.2 or Section 1.4 of this Agreement if, as a result of the application of the preceding sentence, the anticipated aggregate offering price of
the Registrable Securities to be included in the registration does not equal or exceed the anticipated aggregate offering price required to originally trigger the Company’s obligation to initiate such registration as specified in subsection
1.2(a) or subsection 1.4(b)(2), whichever is applicable. 
 1.7    Expenses of Registration.
All expenses other than underwriting discounts and commissions incurred in connection with registrations, filings or qualifications pursuant to Sections 1.2, 1.3 and 1.4 including (without limitation) all registration, filing and
qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company, and the reasonable fees and disbursements of one counsel for the selling Holders selected by them (not to exceed $50,000) with the
approval of the Company, which approval shall not be unreasonably withheld, shall be borne by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant
to Section 1.2 or 1.4 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all participating Holders shall bear such expenses), unless
the Holders of a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to Section 1.2 or one right to a Form S-3 registration under Section 1.4, as
the case may be. 
 1.8    Underwriting Requirements. In connection with any offering
involving an underwriting of shares of the Company’s capital stock, the Company shall not be required under Section 1.3 to include any of the Holders’ securities in such underwriting unless they accept the terms of the underwriting as
agreed upon between the Company and the underwriters selected by the Company (or by other persons entitled to select the underwriters), and then only in such quantity as the underwriters determine in their sole discretion will not jeopardize the
success of the offering by the Company. If the total amount of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the amount of securities sold other than by the Company that the
underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the
underwriters determine in their sole discretion will not jeopardize the success of the offering (the securities so included to be apportioned pro rata among the selling stockholders according to the total amount of securities entitled to be included
therein owned by each selling stockholder or in such other proportions as shall mutually be agreed to by such selling stockholders) but in no event shall (i) the amount of securities of the selling Holders included in the offering be reduced
below 30% of the total amount of securities included in such offering, unless such offering is the initial public offering of the Company’s securities, in which case the selling stockholders may be excluded if the underwriters make the
determination described above and no other stockholder’s securities are included or (ii) any securities held by a Key Holder be included if any securities held by any selling Holder are excluded. For purposes of the preceding parenthetical
concerning 

  
 -8- 

 
apportionment, for any selling stockholder which is a holder of Registrable Securities and which is a venture capital fund, or a partnership or corporation, the Affiliated Funds, members,
partners, retired partners and stockholders of such holder, or the estates and family members of any such partners and retired partners and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “selling
stockholder,” and any pro-rata reduction with respect to such “selling stockholder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and
individuals included in such “selling stockholder,” as defined in this sentence. 
 1.9    Delay
of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or
implementation of this Section 1. 
 1.10    Indemnification. In the event any
Registrable Securities are included in a registration statement under this Section 1: 
 (a)    To the extent
permitted by law, the Company will indemnify and hold harmless each Holder, and the partners, members, officers, directors and stockholders of each such holder, any underwriter (as defined in the Securities Act) for such Holder and each person, if
any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the Exchange
Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a
“Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or
supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the
Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law; and the Company will pay to each such Holder, underwriter or
controlling person, as incurred, any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement
contained in this subsection 1.10(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably
withheld), nor shall the Company be liable to any Holder, underwriter or controlling person for any such loss, claim, damage, liability, or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in
conformity with written information furnished expressly for use in connection with such registration by any such Holder, underwriter or controlling person. 

(b)    To the extent permitted by law, each selling Holder will indemnify and hold harmless the Company, each of its
directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Securities Act, any underwriter, any other Holder selling securities in such registration statement
and any controlling person of any such underwriter or other Holder, against any losses, claims, 

  
 -9- 

 
damages, or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Securities Act, the Exchange Act or other federal or state law, insofar as such
losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written
information furnished by such Holder expressly for use in connection with such registration; and each such Holder will pay, as incurred, any legal or other expenses reasonably incurred by any person intended to be indemnified pursuant to this
subsection 1.10(b), in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this subsection 1.10(b) shall not apply to
amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided, that in no event shall any indemnity
under this subsection 1.10(b) and any amounts payable under subsection 1.10(d) together exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such Holder. 

(c)    Promptly after receipt by an indemnified party under this Section 1.10 of notice of the commencement of any
action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.10, deliver to the indemnifying party a written notice of the commencement
thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with
the reasonable fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such
indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability to
defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 1.10, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it
may have to any indemnified party otherwise than under this Section 1.10. 
 (d)    If the indemnification provided
for in this Section 1.10 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu of
indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault
of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable
considerations; provided, that in no event shall any contribution by a Holder under this Subsection 1.10(d) exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such Holder. The relative
fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or 

  
 -10- 

 
alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and
the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. 

(e)    Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in
the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f)    The obligations of the Company and Holders under this Section 1.10 shall survive the completion of any
offering of Registrable Securities in a registration statement under this Section 1, and otherwise. 

1.11    Reports Under the Exchange Act . With a view
to making available to the Holders the benefits of Rule 144 promulgated under the Securities Act and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without
registration or pursuant to a registration on Form S-3, the Company agrees to: 

(a)    make and keep public information available, as those terms are understood and defined in SEC Rule 144, at all
times after 90 days after the effective date of the IPO so long as the Company remains subject to the periodic reporting requirements under Sections 13 or 15(d) of the Exchange Act; 

(b)    take such action, including the voluntary registration of its Common Stock under Section 12 of the Exchange
Act, as is necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal year in which the
first registration statement filed by the Company for the offering of its securities to the general public is declared effective; 

(c)    file with the SEC in a timely manner all reports and other documents required of the Company under the Securities
Act and the Exchange Act; and 
 (d)    furnish to any Holder upon request, so long as the Holder owns any Registrable
Securities, (i) a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after 90 days after the effective date of the IPO), the Securities Act and the Exchange Act (at any time
after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy
of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the
SEC which permits the selling of any such securities without registration or pursuant to such form. 

1.12    Assignment of Registration Rights. The rights to cause the Company to register
Registrable Securities pursuant to this Section 1 may be assigned (but only with all related obligations) by a Holder to a transferee or assignee (i) of at least 1,000,000 shares of such securities (subject to adjustment for stock splits,
stock dividends, reclassification or the like) (or 

  
 -11- 

 
if the transferring Holder owns less than 1,000,000 shares of such securities, then all Registrable Securities held by the transferring Holder), (ii) that is a subsidiary, parent, partner,
limited partner, retired partner, member, retired member or stockholder of a Holder, (iii) that is an Affiliated Fund, (iv) who is a Holder’s or Founder’s child, stepchild, grandchild, parent, stepparent, grandparent, spouse,
sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law (such a relation, a Holder’s “Immediate Family Member”, which term shall include adoptive and foster relationships), or (v) that is a
trust for the benefit of an individual Holder or Founder or such Holder’s or Founder’s Immediate Family Member, provided the Company is, within a reasonable time after such transfer, furnished with written notice of the name and
address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; and provided, further, that such assignment shall be effective only if the transferee agrees in writing to be
bound by this Agreement and immediately following such transfer the further disposition of such securities by the transferee or assignee is restricted under the Securities Act. For the purposes of determining the number of shares of Registrable
Securities held by a transferee or assignee, the holdings of transferees and assignees of (x) a partnership who are partners or retired partners of such partnership or (y) a limited liability company who are members or retired members of
such limited liability company (including Immediate Family Members of such partners or members who acquire Registrable Securities by gift, will or intestate succession) shall be aggregated together and with the partnership or limited liability
company; provided that all assignees and transferees who would not qualify individually for assignment of registration rights shall have a single attorney-in-fact for
the purpose of exercising any rights, receiving notices or taking any action under Section 1. 

1.13    Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the
Company shall not, without the prior written consent of the Holders of a majority of the outstanding Registrable Securities, enter into any agreement with any holder or prospective holder of any securities of the Company which would allow such
holder or prospective holder (a) to include any of such securities in any registration filed under Section 1.2 hereof, unless under the terms of such agreement, such holder or prospective holder may include such securities in any such
registration only to the extent that the inclusion of his securities will not reduce the amount of the Registrable Securities of the Holders which is included or (b) to make a demand registration which could result in such registration
statement being declared effective prior to the earlier of either of the dates set forth in subsection 1.2(a) or within 120 days of the effective date of any registration effected pursuant to Section 1.2. 

1.14    Lock-Up Agreement. 

(a)    Lock-Up Period; Agreement. In connection with the
initial public offering of the Company’s securities and upon request of the Company or the underwriters managing such offering of the Company’s securities, each Holder agrees not to sell, make any short sale of, loan, grant any option for
the purchase of, or otherwise dispose of any securities of the Company, held immediately before the effective date of the registration statement for such offering (other than those included in the registration) without the prior written consent of
the Company or such underwriters, as the case may be, for such period of time (not to exceed 180 days but subject to such extension or extensions as may be required by the underwriters in order to publish research reports while complying with FINRA
Rule 2711 or NYSE Rule 472(f) or any 

  
 -12- 

 
successor provisions) from the effective date of such registration statement as may be requested by the Company or such managing underwriters and to execute an agreement reflecting the foregoing
as may be requested by the underwriters at the time of the Company’s initial public offering. 

(b)    Limitations. The obligations described in Section 1.14(a) shall apply only if all
officers and directors of the Company and all greater than 1% stockholders of the Company enter into similar agreements, and shall not apply to a registration relating solely to employee benefit plans, or to a registration relating solely to a
transaction pursuant to Rule 145 under the Securities Act. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such
agreements, based on the number of shares subject to such agreements. 
 (c)    Stop-Transfer
Instructions. In order to enforce the foregoing covenants, the Company may impose stop-transfer instructions with respect to the securities of each Holder (and the securities of every other person subject to the restrictions in
Section 1.14(a)). 
 (d)    Transferees Bound. Each Holder agrees that it will not
transfer securities of the Company unless each transferee agrees in writing to be bound by all of the provisions of this Section 1.14, provided that this Section 1.14(d) shall not apply to transfers pursuant to a registration
statement or transfers after the 12-month anniversary of the effective date of the Company’s initial public offering subject to this Section 1.14. 

(e)    Each Holder agrees that a legend reading substantially as follows shall be placed on all certificates representing
all Registrable Securities of each Holder (and the shares or securities of every other person subject to the restriction contained in this Section 1.14): 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD OF UP TO 180 DAYS,
SUBJECT TO EXTENSION, AFTER THE CORPORATION’S INITIAL PUBLIC OFFERING, AS SET FORTH IN AN AGREEMENT BETWEEN THE CORPORATION AND THE ORIGINAL HOLDER OF THESE SECURITIES, A COPY OF WHICH MAY BE OBTAINED AT THE CORPORATION’S PRINCIPAL OFFICE.
SUCH LOCK-UP PERIOD IS BINDING ON TRANSFEREES OF THESE SECURITIES. 

1.15    Termination of Registration Rights. No Holder shall be entitled to exercise any right
provided for in this Section 1 after the earlier of (i) three (3) years following the consummation of an IPO, (ii) with respect to any Holder, at such time after the IPO as Rule 144 or another similar exemption under the
Securities Act is available for the sale of all of such Holder’s shares during a three-month period without registration and such Holder’s shares represent less than 1% of the Common Stock of the Company then outstanding (calculated on an as-converted basis), or (iii) upon termination of the Agreement, as provided in Section 3.1. 

  
 -13- 

 2.    Covenants of the Company. 

2.1    Delivery of Financial Statements. The Company shall, promptly following any request by a Major
Investor, deliver to such Major Investor (other than a Major Investor reasonably deemed by the Company to be a Competitor of the Company): 

(a)    as soon as practicable, but in any event within 120 days after the end of each fiscal year of the Company (or such
longer period of time as may be required by the Company’s independent public accountants), an income statement for such fiscal year, a balance sheet of the Company and statement of stockholder’s equity as of the end of such year, and a
statement of cash flows for such year, such year-end financial reports to be in reasonable detail, prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and
audited and certified by an independent public accounting firm of nationally recognized standing selected by the Company; 

(b)    within 45 days after the end of each quarter of each fiscal year of the Company, an unaudited income statement and
statement of cash flows for such fiscal quarter and an unaudited balance sheet as of the end of such fiscal quarter, in reasonable detail; 

(c)    within 30 days after the end of each of the four (4) quarters of each fiscal year of the Company, a statement
showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period (including, in the case of convertible debt securities, the face
amount, issue date, maturity date, interest rate, conversion discount and valuation cap to the extent applicable), the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and
the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate
their respective percentage equity ownership in the Company; 
 (d)    within 30 days from the start of each fiscal
year, a budget and business plan for such fiscal year; and 
 (e)    such other information relating to the financial
condition, business, prospects, or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Subsection 2.1 to provide
information which (i) it reasonably considers to be a trade secret or similarly highly confidential information or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

2.2    Inspection. The Company shall permit each Major Investor (except for a Major Investor
reasonably deemed by the Company to be a Competitor of the Company), at such Major Investor’s expense, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs,
finances and accounts with its officers, all at such reasonable times as may be requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Section 2.2 to provide access to any
information which it reasonably considers to be a trade secret or similar confidential information. 

  
 -14- 

 2.3    Right of First Offer. Subject to the terms
and conditions specified in this Section 2.3, the Company hereby grants to each Major Investor a right of first offer with respect to future sales by the Company of its Shares (as hereinafter defined). Each time the Company proposes to offer
any shares of, or securities convertible into or exercisable for any shares of, any class of its capital stock (“Shares”), the Company shall first make an offering of such Shares to each Major Investor in accordance with the
following provisions: 
 (a)    The Company shall deliver a notice (the “RFO Notice”) to the Major
Investors stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such Shares. 

(b)    Within 15 days after delivery of the RFO Notice, the Major Investor may elect to purchase or obtain, at the price
and on the terms specified in the RFO Notice, up to that portion of such Shares which equals the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion and exercise of all convertible or exercisable
securities then held, by such Major Investor bears to the sum of (A) the total number of shares of Common Stock then outstanding (assuming full conversion and exercise of all convertible or exercisable securities) and (B) shares of Common
Stock issuable to employees, consultants or directors pursuant to a stock option plan, restricted stock plan, or other stock plan approved by the Board of Directors of the Company. Such purchase shall be completed at the same closing as that of any
third party purchasers or at an additional closing. At the expiration of such fifteen (15) calendar day period, the Company shall promptly, in writing, notify each Major Investor that elects to purchase all the shares available to it (a
“Fully-Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) calendar day period commencing after the Company has given such notice to the Fully-Exercising Investors, each
Fully-Exercising Investor may elect to purchase that portion of the Shares for which Major Investors were entitled to subscribe, but which were not subscribed for by the Major Investors, that is equal to the proportion that the number of shares of
Registrable Securities issued and held by such Fully-Exercising Investor bears to the total number of shares of Common Stock of the Company then outstanding (assuming full conversion and exercise of all convertible and exercisable securities then
outstanding). 
 (c)    The Company may, during the 45-day period following the
expiration of the period provided in subsection 2.3(b) hereof, offer the remaining unsubscribed portion of the Shares to any person or persons at a price not less than, and upon terms no more favorable to the offeree than those specified in the
RFO Notice. If the Company does not enter into an agreement for the sale of the Shares within such period, or if such agreement is not consummated within 60 days after the execution thereof, the right provided hereunder shall be deemed to be revived
and such Shares shall not be offered unless first reoffered to the Major Investors in accordance herewith. 
 (d)    The
right of first offer in this Section 2.3 shall not be applicable to (i) Exempted Securities (as defined in the Restated Certificate); (ii) shares of Common Stock issued in the IPO; and (iii) the issuance of shares of Series C
Preferred Stock to Purchasers pursuant to 

  
 -15- 

 
Subsection 1.2(c) of the Series C Agreement and shares of Common Stock issued or issuable upon conversion thereof. In addition to the foregoing, the right of first offer in this
Section 2.3 shall not be applicable with respect to any Major Investor and any subsequent securities issuance, if (i) at the time of such subsequent securities issuance, the Major Investor is not an “accredited investor,” as that
term is then defined in Rule 501(a) under the Securities Act, and (ii) such subsequent securities issuance is otherwise being offered only to accredited investors. 

2.4    FCPA. The Company represents that it shall not (and shall not permit any of its subsidiaries
or affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to, directly or
indirectly, to any third party, including any Non-U.S. Official (as (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case, in
violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) cease all of its or their respective
activities, as well as remediate any actions taken by the Company, its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in violation of the FCPA, the
U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) maintain systems of internal controls (including, but not
limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to provide responsive
information and/or certifications concerning its compliance with applicable anti-corruption laws. The Company shall promptly notify each Investor if the Company becomes aware of any Enforcement Action (as defined in the Purchase Agreement). The
Company shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future, to comply with the FCPA. The Company shall use its best efforts to cause any direct or indirect
subsidiary, whether now in existence or formed in the future, to comply in all material respects with all applicable laws. 

2.5    Key Person Insurance. The Company has as of the date hereof or shall within 120 days of the
date hereof obtain from financially sound and reputable insurers term life insurance on the life of each of Terry Rosen and Juan C. Jaen in an amount and on terms reasonably acceptable to GV. Such policies shall name the Company as loss payee and
shall not be cancelable by the Company without prior approval of the Company’s Board of Directors. 

2.6    Termination of Covenants. 

(a)    The covenants set forth in Sections 2.1 through Section 2.4 shall terminate as to each Holder and be of
no further force or effect (i) immediately prior to the consummation of an Qualified Public Offering (as defined in the Restated Certificate), or (ii) upon termination of the Agreement, as provided in Section 3.1. 

(b)    The covenants set forth in Sections 2.1 and 2.2 shall terminate as to each Holder and be of no further force
or effect when the Company first becomes subject to the periodic reporting requirements of Sections 13 or 15(d) of the Exchange Act, if this occurs earlier than the events described in Section 2.6(a) above. 

  
 -16- 

 3.    Miscellaneous. 

3.1    Termination. This Agreement shall terminate, and have no further force and effect, upon
the earlier of (i) the liquidation, dissolution or winding up of the Company, or (ii) the closing of a Liquidation Transaction, as defined in the Restated Certificate. 

3.2    Entire Agreement. This Agreement constitutes the entire agreement between the parties hereto
pertaining to the subject matter hereof, and any and all other written or oral agreements relating to the subject matter hereof existing between the parties hereto are expressly canceled. 

3.3    Successors and Assigns. Except as otherwise provided in this Agreement, the terms and
conditions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties (including transferees of any of the Preferred Stock or any Common Stock issued upon conversion thereof).
Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement,
except as expressly provided in this Agreement. 
 3.4    Amendments and Waivers. Any term
of this Agreement may be amended or waived only with the written consent of the Company and the holders of at least 65% of the Registrable Securities then outstanding, not including the Key Holders’ Stock; provided, however, that
(a) if such amendment or waiver has the effect of affecting the Key Holders’ Stock (i) in a manner different than securities issued to the Investors and (ii) in a manner adverse to the interests of the holders of the Key
Holders’ Stock, then such amendment shall require the consent of the holder or holders of a majority of the Key Holders’ Stock; (b) the provisions of Section 1.1(c) and this Section 3.4(b) may not be amended or waived (either generally or in a particular instance, and either retroactively or prospectively) without the written consent of GV; (c) any amendment or waiver of the rights
granted to the Major Investors in Section 2 above shall require the consent of the Company and holders of a majority of the Registrable Securities held by the Major Investors (and no other parties), provided that the rights granted to the Major
Investors in Section 2.3 may not be waived with respect to a particular transaction unless all Major Investors are provided with the opportunity to purchase Shares on similar terms and in proportionally similar amounts as the other Major
Investors who are participating in such offering; and (d) any amendment of the definition of Major Investor in Section 1.1(l) shall require the consent of the Company and holders of a majority of the Registrable Securities held by the
Major Investors (and no other parties), provided that if the amendment would cause a Major Investor to no longer qualify as a Major Investor, then the amendment shall also require the consent of such Major Investor. Notwithstanding the foregoing,
this Agreement may be amended with only the written consent of the Company for the sole purpose of including additional purchasers of Series C Preferred Stock pursuant to the Series C Agreement as “Investors” and “Holders.” Any
amendment or waiver effected in accordance with this paragraph shall be binding upon each party to the Agreement, whether or not such party has signed such amendment or waiver, each future holder of all such Registrable Securities, and the Company.

  
 -17- 

 3.5    Notices. All notices or other communications
hereunder shall be in writing and mailed by registered or certified mail, postage prepaid, sent by facsimile or electronic mail (if to an Investor or Key Holder) or otherwise delivered by hand, messenger or courier service addressed: 

(a)    if to an Investor or Key Holder, to the Investor’s or Key Holder’s address, facsimile number or
electronic mail address as set forth on the Investor’s or Key Holder’s signature page to this Agreement or on Exhibit A to the Series C Agreement (or to any other address, facsimile number or electronic mail address for the Investor
or Key Holder in the Company’s records), as may be updated in accordance with the provisions hereof; 
 (b)    if
to the Company, to the attention of the Chief Executive Officer of the Company at the address set forth on the signature page to this Agreement, as may be updated in accordance with the provisions hereof. 

Each such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given (i) if
delivered by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid, specifying next-business-day delivery, one business day after
deposit with the courier), (ii) if delivered by mail, at the earlier of its receipt or five days after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail, (iii) if sent by facsimile, upon
confirmation of facsimile transmission if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient’s next business day, or (iv) if sent by electronic mail, upon
transmission if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient’s next business day. In the event of any conflict between the Company’s books and
records and this Agreement or any notice delivered hereunder, the Company’s books and records will control absent fraud. 

3.6    Severability. If one or more provisions of this Agreement are held to be unenforceable
under applicable law, such provision shall be excluded from this Agreement, and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 

3.7    Additional Investors. Notwithstanding anything to the contrary contained herein, if the
Company issues additional shares of Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement
and thereafter shall be deemed an “Investor” for all purposes hereunder. 
 3.8    Governing
Law. This Agreement and all acts and transactions pursuant hereto shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of laws. 

3.9    Counterparts. This Agreement may be executed by facsimile or electronic mail in two or
more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

  
 -18- 

 3.10    Titles and Subtitles. The titles and
subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 

3.11    Aggregation of Stock. All shares of Registrable Securities held or acquired by
Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

3.12    Effect on Prior Agreement. Upon the effectiveness of this Agreement, the Prior
Agreement shall be superseded and replaced in its entirety by this Agreement and shall be of no further force or effect. 
 [Signature Pages
Follow] 

  
 -19- 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	COMPANY:
	
	ARCUS BIOSCIENCES, INC.
		
	By:	 	 /s/ Terry Rosen

	Name:	 	Terry Rosen
	Title:	 	Chief Executive Officer

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	CELGENE CORPORATION
		
	By:	 	 /s/ Robert Hershberg

	Name:	 	Robert Hershberg
	Title:	 	EVP, BD

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	 THE ROSEN 1996 FAMILY TRUST

DATED JUNE 28, 1996

		
	By:	 	 /s/ Terry Rosen

	Name:	 	Terry Rosen
	Title:	 	Trustee

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	JUAN CARLOS JAEN AND ANITA GALEANA, TRUSTEES OF THE JUAN CARLOS JAEN AND ANITA GALEANA 2000 TRUST
		
	By:	 	 /s/ Juan C. Jaen

	Name:	 	Juan C. Jaen
	Title:	 	Trustee

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	YASUNORI KANEKO AND YUMI KANEKO, TRUSTEES OF THE KANEKO FAMILY TRUST U/D/T DATED JANUARY 20, 1992
		
	By:	 	 /s/ Yasunori Kaneko

	Name:	 	Yasunori Kaneko
	Title:	 	Trustee
		
	By:	 	 /s/ Yumi Kaneko

	Name:	 	Yumi Kaneko
	Title:	 	Trustee

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	DROIA GROUP
		
	By:	 	 /s/ Janwillem Naesens

	Name:	 	Janwillem Naesens,
representing Onko Bvba
	Title:	 	Chairman of the Board of Directors

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	FORESITE CAPITAL FUND III, L.P.
		
	By:	 	Foresite Capital Management III, LLC
	Its:	 	General Partner
		
	By:	 	 /s/ Dennis D. Ryan

	Name:	 	Dennis D. Ryan
	Title:	 	Chief Financial Officer

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	G&H PARTNERS
		
	By:	 	 /s/ Stefan J. Palmer Jr.

	Name:	 	Stefan J. Palmer Jr.
	Title:	 	Director of Investment & G.P.

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	GV 2016, L.P.
		
	By:	 	GV 2016 GP, L.P., its General Partner
	By:	 	GV 2016 GP, L.L.C., its General Partner
		
	By:	 	 /s/ Daphne M. Chang

	Name:	 	Daphne M. Chang
	Title:	 	Authorized Signatory
	
	GV 2017, L.P.
		
	By:	 	GV 2017 GP, L.P., its General Partner
	By:	 	GV 2017 GP, L.L.C., its General Partner
		
	By:	 	 /s/ Daphne M. Chang

	Name:	 	Daphne M. Chang
	Title:	 	Authorized Signatory

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	INVUS OPPORTUNITIES FUND III, LP
		
	By:	 	Invus Opportunities GP III, LLC
		
	By:	 	 /s/ Sacha Lainovic

	Name:	 	Sacha Lainovic
	Title:	 	Managing Director
	
	INVUS OPPORTUNITIES FUND III US, LP
		
	By:	 	Invus Opportunities GP III, LLC
		
	By:	 	 /s/ Sacha Lainovic

	Name:	 	Sacha Lainovic
	Title:	 	Managing Director

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	THE COLUMN GROUP II, LP
		
	By:	 	The Column Group II GP, LP
	Its:	 	General Partner
		
	By:	 	The Column Group, LLC
	Its:	 	General Partner
		
	By:	 	 /s/ James Evangelista

	Name:	 	James Evangelista
	Title:	 	Chief Financial Officer
	
	PONOI CAPITAL, LP
		
	By:	 	Ponoi Management, LLC
	Its:	 	General Partner
		
	By:	 	 /s/ James Evangelista

	Name:	 	James Evangelista
	Title:	 	Chief Financial Officer

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	EcoR1 Capital Fund, L.P.
		
	By:	 	EcoR1 Capital, LLC, its General Partner
		
	By:	 	 /s/ Oleg Nodelman

	Name:	 	Oleg Nodelman
	Title:	 	Managing Director
	
	EcoR1 Capital Fund Qualified, L.P.
		
	By:	 	EcoR1 Capital, LLC, its General Partner
		
	By:	 	 /s/ Oleg Nodelman

	Name:	 	Oleg Nodelman
	Title:	 	Managing Director

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	BIOTECHNOLOGY VALUE FUND, LP
		
	By:	 	 /s/ Mark Lampert

	Name:	 	Mark Lampert
	Title:	 	President BVF Inc., General Partner BVF Partners LP
	
	BIOTECHNOLOGY VALUE FUND II, LP
		
	By:	 	 /s/ Mark Lampert

	Name:	 	Mark Lampert
	Title:	 	President BVF Inc., General Partner BVF Partners LP
	
	BIOTECHNOLOGY VALUE TRADING FUND OS, LP
		
	By:	 	 /s/ Mark Lampert

	Name:	 	Mark Lampert
	Title:	 	President BVF Inc., General Partner BVF Partners LP

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	INVESTMENT 10, LLC
		
	By:	 	 /s/ Mark Lampert

	Name:	 	Mark Lampert
	Title:	 	President BVF Inc.,
		 	General Partner BVF Partners LP
	
	MSI-BVF SPV, LLC
		
	By:	 	 /s/ Mark Lampert

	Name:	 	Mark Lampert
	Title:	 	President BVF Inc.,
		 	General Partner BVF Partners LP

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND II, L.P.
	
	By its General Partner,
	Decheng Capital Management II (Cayman), LLC
		
	By:	 	 /s/ Xiangmin Cui

	Name:	 	Xiangmin Cui
	Title:	 	Managing Director

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	AISLING CAPITAL IV, LP
		
	By:	 	 /s/ Robert Wenzel

	Name:	 	Robert Wenzel
	Title:	 	CFO

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	LEERINK HOLDINGS LLC
		
	By:	 	 /s/ Timothy A.G. Gerhold

	Name:	 	Timothy A.G. Gerhold
	Title:	 	General Counsel
	
	LEERINK SWANN CO-INVESTMENT FUND, LLC
		
	By:	 	 /s/ Jeffrey A. Leerink

	Name:	 	Jeffrey A. Leerink
	Title:	 	Manager

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	RIBAS-ARMENGOL FAMILY TRUST
		
	By:	 	 /s/ Antoni Ribas

	Name:	 	Antoni Ribas
	Title:	 	Trustee

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	FALBERG-PREDOVICH FAMILY TRUST DTD 6-11-12
		
	By:	 	 /s/ Kathryn E. Falberg

	Name:	 	Kathryn E. Falberg
	Title:	 	Trustee

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

	
	INVESTOR:
	
	 /s/Joyson Karakunnel

	 JOYSON KARAKUNNEL

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	TAIHO VENTURES, LLC
		
	By:	 	 /s/ Sakae Asanuma

	Name:	 	Sakae Asanuma
	Title:	 	President

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	CURIOSITY GROUP TRUST I – 2017A U/T/A OCTOBER 31, 2016
		
	By:	 	 /s/ Brook H. Byers

	Name:	 	Brook H. Byers
	Title:	 	Trustee

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	HADLEY HARBOR MASTER INVESTORS (CAYMAN) II L.P.
		
	By:	 	Wellington Management Company LLP, as investment adviser
		
	By:	 	 /s/ Emily Babalas

	Name:	 	Emily Babalas
	Title:	 	Managing Director and Counsel

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	 INVESTOR:

	
	 HH RSV-ARK HOLDINGS
LIMITED

		
	By:	 	 /s/ Colm O’Connell

	 Name:
	 	 Colm O’Connell

	 Title:
	 	 Director

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	 INVESTOR:

	
	 FAIR BLESS LIMITED

		
	By:	 	 /s/ Yuan Sun

	 Name:
	 	 Yuan Sun

	 Title:
	 	 Director

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	INVESTOR:
	
	CURIOSITY GROUP TRUST II – 2017A U/T/A OCTOBER 31, 2016
		
	By:	 	 /s/ Shawn S. Byers

	Name:	 	Shawn S. Byers
	Title:	 	Trustee

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	KEY HOLDERS:
	
	THE ROSEN 1996 FAMILY TRUST DATED JUNE 28, 1996
		
	By:	 	 /s/ Terry Rosen

	Name:	 	Terry Rosen
	Title:	 	Trustee

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the
date first written above. 
  

			
	KEY HOLDERS:
	
	 JUAN CARLOS JAEN AND ANITA

GALEANA, TRUSTEES OF THE JUAN CARLOS JAEN AND ANITA GALEANA

2000 TRUST

		
	By:	 	 /s/Juan C. Jaen

	Name:	 	Juan C. Jaen
	Title:	 	Trustee

  

SIGNATURE PAGE TO ARCUS BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 

 Exhibit A 

SCHEDULE OF INVESTORS 
 The
Rosen 1996 Family Trust Dated June 28, 1996 
 Juan Carlos Jaen and Anita Galeana, Trustees of the Juan Carlos Jaen and Anita Galeana
2000 Trust 
 Yasunori Kaneko and Yumi Kaneko, Trustees of the Kaneko Family Trust U/D/T dated January 20, 1992 

Brian Landan 
 Stephen and Sandra
Young Revocable Trust 
 Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin Trustees 

McEvoy Worsencroft Family Trust DTD 7/29/94, Dennis L. McEvoy and Kim Worsencroft 

Trustees 
 Jay P. Powers 

Sharlene Stein Trust A Restated 03-16-2005 

Nigel and Josephine Walker Living Trust dtd. 02/19/2013 

Frank and Lorelei Chambers 
 Frank
E. Galeana 
 Manolita Galeana, Trustee of the Manolita Galeana November 4, 1993 Revocable Living Trust 

Tim Yuen and Samantha Stein 
 The
Simke Family Revocable Trust, Separate Property of Jack G. Simke 
 Karl Handelsman 

Julio C. Medina 
 Shichang Miao 

Harvey S. Rosen and Marsha E. Novick, JT WROS 

Matthew Walters 
 Cozad Investments,
LP 
 Brandon Reid Rosen Trust U/A/D 11-22-1996, Sharlene
Stein Trustee 
 Cameron Clark Rosen Trust U/A/D 6-22-1999,
Sharlene Stein Trustee 
 Connor Edwin Rosen Trust U/A/D
11-22-1996, Sharlene Stein Trustee 
 Frank Edward Galeana,
Trustee of the Grace Alexandra Jaen Irrevocable Trust, dated December 11, 2013 
 Frank Edward Galeana, Trustee of the John David Jaen
Irrevocable Trust, dated December 11, 2013 
 Frank Edward Galeana, Trustee of the Katherine Emily Jaen Irrevocable Trust, dated
December 11, 2013 
 Frank Edward Galeana, Trustee of the Marie Elizabeth Jaen Irrevocable Trust, dated December 11, 2013 

Frederick J. Dotzler and Cassandra L. Dotzler, Trustees of the Dotzler Family Trust UDT Dated 

August 9, 2001 
 Mark E. Hayes
and Patricia M. Hayes 
 David L. Lacey 

The Sanjay Popli and Rekha Hemrajani Revocable Living Trust 

Judy M. Wong Living Trust Dated May 1, 2015 

The Simke Family Revocable Trust, Separate Property of Robin D. Raphael-Simke 

 Gary Goodman and Bradley Matteoni 

Joan L. Hixson, Trustee of the Joan L. Hixson Trust, dated 7/20/1978 

Bruce I. Rosen 
 Tim Sullivan 

Larry Martial Etcheverry and Ariel Anne Etcheverry Family Trust U/A dtd March 8, 2005 

Hua Tu and Vickie Tu, Trustees of the Hua and Vickie Tu Family 2008 TRUST 

Leah Duker 
 Mary Tsay 

Jennifer Berrueta Vergara 
 RL
Freitas and RG Freitas Co-Trustees of the Robert Freitas and Rita Freitas Rev. Trust 
 Kurt and
Mollie Jurgenson 
 The 1989 Bayol Living Trust 

Entrust Administration FBO Kurt Jurgenson Roth IRA Acct # 28642 

Entrust Administration FBO Mollie A. Jurgenson Roth IRA Acct # 30743 

Daniel W. Burke 
 The Column Group
II, LP 
 Ponoi Capital, LP 

Foresite Capital Fund III, L.P. 

G&H Partners 
 Novartis
Institutes for BioMedical Research, Inc. 
 Celgene Corporation 

Frederick J. Dotzler and Cassandra L. Dotzler, Trustees of the Dotzler Family Trust UDT Dated August 9, 2001 

Mark and Andrea Penfold, Joint Community Property with Rights of Survivorship 

GV 2016, L.P. 
 GV 2017, L.P. 

The Board of Trustees of the Leland Stanford Junior University (PVF) 

DROIA Group 
 Taiho Ventures, LLC

 Invus Opportunities Fund III US, LP 

Invus Opportunities Fund III, LP 

Ulrike Schindler 
 Doug Studebaker

 Be Curious LLC 
 West Shore
1986 Partners, LP 
 Tim & Anu Hoey 

RTA Capital LLC 
 Bradley Matteoni
and Gary Goodman as Trustees of the Bradley Matteoni and Gary Goodman Revocable Living Trust dated March 15, 2016 
 Miao SC Investment
LLC 
 EcoR1 Capital Fund, L.P. 

EcoR1 Capital Fund Qualified, L.P. 

Biotechnology Value Fund, LP 

Biotechnology Value Fund II, LP 

Biotechnology Value Trading Fund OS, LP 

Investment 10, LLC 

 MSI-BVF SPV, LLC 

Decheng Capital China Life Sciences USD Fund II, L.P. 

Aisling Capital IV, LP 
 Leerink
Holdings LLC 
 Leerink Swann Co-Investment Fund, LLC 

Ribas-Armengol Family Trust 

Kathryn E. Falberg, trustee of the Falberg-Predovich Family Trust dtd
6-11-12 
 Joyson Karakunnel 

Brook H. Byers, trustee of the Curiosity Group Trust I – 2017A U/T/A October 31, 2016 

Shawn S. Byers, trustee of the Curiosity Group Trust II – 2017A U/T/A October 31, 2016 

Hadley Harbor Master Investors (Cayman) II L.P. 

HH RSV-ARK Holdings Limited 

Fairy Bless Limited

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}]]